Funding from EDCTP will allow testing of a novel whole-cell inactivated oral vaccine in clinical trials in Europe and Africa

The ZIKAVAX consortium announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on one of the project partners -Themis- proprietary measles vector platform.

Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials in Europe and Bangladesh

We invite you to read more about how we advanced the development of urgently needed vaccines and other activites we undertook in 2018.

Please use this link to access and download the full report.


We hope you will have an interesting read!

Join the SENET project´s Group Meetings and have a say within the health research and innovation landscape between the EU and China!

“Zero Malaria Starts with Me”

EVI has an exciting new Project Manager position. Deadline for applications: 6th May 2019, 17:00 CET. For more information please below advert. We look forward to receiving your application.

Goal of new project is to further advance the development of a new vaccine candidate based on the PfRipr5 protein of Plasmodium falciparum.

This work -supported by the Bundesministerium für Bildung und Forschung (BMBF), Germany, and through funding from Irish Aid, Ireland- paved the way for the clinical development of a vaccine against placental malaria

EVI supports new EC-funded project that aims to strengthen international research and innovation cooperation between China and the EU